1316652-41-1

Usage

Uses

Used in Organic Synthesis:
N-Hydroxy-3-[1-(phenylthio)Methyl-1H-1,2,3-triazol-4-yl]benzaMide serves as a versatile building block in organic synthesis, facilitating the creation of more complex chemical structures for various purposes.
Used in Drug Discovery and Development:
In the pharmaceutical industry, N-Hydroxy-3-[1-(phenylthio)Methyl-1H-1,2,3-triazol-4-yl]benzaMide is utilized as a starting material for the preparation of potential drug candidates, capitalizing on its unique structural elements to explore novel therapeutic agents.
Used in Materials Science:
N-Hydroxy-3-[1-(phenylthio)Methyl-1H-1,2,3-triazol-4-yl]benzaMide also finds applications in materials science, where its properties can be harnessed to develop new materials with specific characteristics for various uses.
Used in Chemical Research:
N-Hydroxy-3-[1-(phenylthio)Methyl-1H-1,2,3-triazol-4-yl]benzaMide is valuable in chemical research for studying reaction mechanisms, exploring new synthetic routes, and understanding the properties of related chemical entities.

Upstream product

• 1193-82-4 racemic methyl phenyl sulfoxide 
• 480425-35-2 methyl 3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzoate 
• 1316652-59-1 3-ethynyl-N-(2-tetrahydropyranyloxy)benzamide 
• 77123-59-2 methyl 3-<(trimethylsilyl)ethynyl>benzoate 
• 618-51-9 3-Iodobenzoic acid 
• 1316652-54-6 3-ethynyl-N-hydroxybenzamide 
• 77422-70-9 azidomethyl phenyl sulphide 

Relevant academic research and scientific papers

Process-Controlled Regiodivergent Copper-Catalyzed Azide-Alkyne Cycloadditions: Tailor-made Syntheses of 4- And 5-Bromotriazoles from Bromo(phosphoryl)ethyne

We developed a regiodivergent syntheses of 4- and 5-bromo-substituted 1,2,3-triazoles in copper-catalyzed azide-alkyne cycloadditions (CuAACs) by taking advantage of bromo(phosphoryl)ethyne 1 as a bromoethyne equivalent. A one-shot dephosphorylative CuAAC

Pummerer rearrangement using bis(p-nitrophenyl) phosphorazidate as an azidation reagent: A novel synthesis of azidomethyl sulfides

A novel method for the synthesis of azidomethyl sulfides by Pummerer rearrangement using bis(p-nitrophenyl) phosphorazidate (p-NO2DPPA) as an azidation reagent was developed. Various methyl sulfoxides were converted into the corresponding azidomethyl sulfides. Importantly, this reaction enables the preparation of azidomethyl sulfides without the use of toxic or explosive azide sources.

Using the same hydroxamic acid derivative and HDAC8 inhibitor (by machine translation)

Disclosed are: a compound which is capable of inhibiting the function of HDAC8; and an HDAC8 inhibitor. Specifically disclosed is a hydroxamic acid derivative which is characterized by being composed of a compound represented by general formula (1) (wherein X represents an aromatic substituent or an optionally substituted 3-8 membered ring, and n represents an integer of 0-20), or a pharmaceutically acceptable salt, hydrate, solvate or prodrug thereof.

Rapid discovery of highly potent and selective inhibitors of histone deacetylase 8 using click chemistry to generate candidate libraries

To find HDAC8-selective inhibitors, we designed a library of HDAC inhibitor candidates, each containing a zinc-binding group that coordinates with the active-site zinc ion, linked via a triazole moiety to a capping structure that interacts with residues on the rim of the active site. These compounds were synthesized by using click chemistry. Screening identified HDAC8-selective inhibitors including C149 (IC50 = 0.070 μM), which was more potent than PCI-34058 (6) (IC50 = 0.31 μM), a known HDAC8 inhibitor. Molecular modeling suggested that the phenylthiomethyl group of C149 binds to a unique hydrophobic pocket of HDAC8, and the orientation of the phenylthiomethyl and hydroxamate moieties (fixed by the triazole moiety) is important for the potency and selectivity. The inhibitors caused selective acetylation of cohesin in cells and exerted growth-inhibitory effects on T-cell lymphoma and neuroblastoma cells (GI50 = 3-80 μM). These findings suggest that HDAC8-selective inhibitors have potential as anticancer agents.